Anavex Life Sciences (AVXL) Assets Average (2012 - 2025)

Anavex Life Sciences (AVXL) has 13 years of Assets Average data on file, last reported at $118.4 million in Q4 2025.

• For the quarter ending Q4 2025, Assets Average fell 8.78% year-over-year to $118.4 million; the trailing twelve-month figure through Dec 2025 stood at $118.4 million (down 8.78% YoY), and the FY2025 full-year result was $119.7 million, down 17.44% from the prior year.
• Assets Average advanced to $118.4 million in Q4 2025, from $103.1 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $164.0 million in Q3 2021 to a low of $69.0 million in Q1 2021.
• A 5-year average of $138.6 million and a median of $148.4 million in 2022 frame the typical range for Assets Average.
• Across the five-year window, Assets Average surged 395.73% in 2021 and slipped 25.57% in 2025, its largest moves.
• Tracing AVXL's Assets Average over 5 years: stood at $159.3 million in 2021, then slipped by 5.47% to $150.5 million in 2022, then gained by 0.46% to $151.2 million in 2023, then dropped by 14.17% to $129.8 million in 2024, then retreated by 8.78% to $118.4 million in 2025.
• Business Quant data shows AVXL's Assets Average at $118.4 million in Q4 2025, $103.1 million in Q3 2025, and $109.8 million in Q2 2025.